Six, not eight cycles of bi-weekly CHOP with rituximab (RCHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).

被引：0

作者：

Pfreundschuh, M ^{[1
]}

Kloess, M ^{[1
]}

Schmits, R ^{[1
]}

Zeynalova, S ^{[1
]}

Lengfelder, E ^{[1
]}

Franke, A ^{[1
]}

Steinhauer, H ^{[1
]}

Reiser, M ^{[1
]}

Clemens, M ^{[1
]}

Nickenig, C ^{[1
]}

de Wit, M ^{[1
]}

Hoffmann, M ^{[1
]}

Mertelsmann, R ^{[1
]}

Metzner, B ^{[1
]}

Ho, A ^{[1
]}

Truemper, L ^{[1
]}

Eimermacher, H ^{[1
]}

Mergenthaler, H ^{[1
]}

Liersch, R ^{[1
]}

Duehrsen, U ^{[1
]}

Balleisen, L ^{[1
]}

Hartmann, F ^{[1
]}

Poeschel, V ^{[1
]}

Schmitz, N ^{[1
]}

Loeffler, M ^{[1
]}

机构：

[1] Univ Saarland, Sch Med, Med Klin 1,DSHNHl, German High Grade Non Hodgkin Lymphoma Study Grp, D-6650 Homburg, Saarland, Germany

来源：

BLOOD | 2005年 / 106卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9A / 9A

页数：1

共 50 条

[1] Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the german high-grade non-Hodgkin lymphoma study group (DSHNHL).
Pfreundschuh, Michael
Kloess, Marita
Zeynalova, Samira
Lengfelder, Eva
Franke, Astrid
Reiser, Marcel
Steinhauer, Hjalmar
Clemens, Michael
Nickenig, Christina
de Wit, Maike
Metzner, Bernd
Hensel, Manfred
Mergenthaler, Hans-Guenther
Liersch, Ruediger
Duehrsen, Ulrich
Balleisen, Leopold
Engelhardt, Monika
Poeschel, Viola
Schubert, Joerg
Truemper, Lorenz
Schmitz, Norbert
Loeffler, Markus
BLOOD, 2006, 108 (11) : 64A - 65A
[2] Bi-weekly dosing preserves the efficacy of rituximab in elderly patients with poor-prognosis DLBCL: Results from the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study group (DSHNHL).
Schubert, J.
Reiser, M.
Wenger, M.
Kloess, M.
Lengfelder, E.
Franke, A.
Steinhauer, H. B.
Clemens, M.
Schmitz, N.
Loeffler, M.
Pfreundschuh, M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 431S - 431S
[3] Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with Diffuse Large B-cell Lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL)
Schubert, J.
Ziepert, M.
Lengfelder, E.
Mohren, M.
Peter, N.
Reiser, M.
Clemens, M.
Nickenig, C.
Bokemeyer, C.
Ho, A. D.
Eimermacher, H.
Truemper, L.
Hoffmann, M.
Mertelsmann, R.
Metzner, B.
Mergenthaler, H. -G.
Liersch, R.
Duehrsen, U.
Balleisen, L.
Hartmann, F.
Poeschel, V.
Schmitz, N.
Loeffler, M.
Pfreundschuh, M.
ONKOLOGIE, 2008, 31 : 120 - 120
[4] Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)
Schubert, Joerg
Ziepert, Marita
Lengfelder, Eva
Mohren, Martin
Peter, Norma
Reiser, Marcel
Clemens, Michael
Nickenig, Christina
dewit, Maike
Ho, Anthony
Eimermacher, Hartmut
Truemper, Lorenz
Hoffmann, Martin
Mertelsmann, Roland
Metzner, Bernd
Mergenthaler, Hans-Guenther
Liersch, Ruediger
Duehrsen, Ulrich
Balleisen, Leopold
Hartmann, Frank
Poeschel, Viola
Schmitz, Norbert
Loeffler, Markus
Pfreundschuh, Michael
BLOOD, 2007, 110 (11) : 242A - 242A
[5] Six or eight cycles of CHOP plus rituximab for elderly patients with diffuse large B-cell lymphoma: Updated results of the RICOVER-60 trial
Muneer, Sabeeha
Cunningham, Sonia
CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 14 - 15
[6] SEX-SPECIFIC EFFECTS OF RITUXIMAB ON TREATMENT OUTCOME OF ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL)
Murawski, N.
Schubert, J.
Zeynalova, S.
Poeschel, V.
Borchmann, P.
Ho, A. D.
Nickenig, C.
Wessendorf, S.
Metzner, B.
Loeffler, M.
Pfreundschuh, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 436 - 436
[7] Single Nucleotide Polymorphisms (SNPs) of FCγRIIA and FCγRIIIA in Patients with Diffuse Large B-Cell Lymphoma Have No Impact On Treatment Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP with and without Rituximab: Results From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymhoma Study Group (DSHNHL)
Ahlgrimm, Manfred
Regitz, Evi
Preuss, Klaus-Dieter
Grass, Sandra
Poeschel, Viola
Kreuz, Markus
Pfreundschuh, Michael
BLOOD, 2009, 114 (22) : 1521 - 1521
[8] CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Boehme, Volkmar
Schmitz, Norbert
Zeynalova, Samira
Loeffler, Markus
Pfreundschuh, Michael
BLOOD, 2009, 113 (17) : 3896 - 3902
[9] INFERIOR OUTCOME OF ELDERLY DLBCL PTS WITH 25-OH VITAMIN D DEFICIENCY TREATED WITH CHOP PLUS RITUXIMAB: RESULTS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP DSHNHL
Bittenbring, J.
Achenbach, M.
Altmann, B.
Ziepert, M.
Reichrath, J.
Geisel, J.
Regitz, E.
Murawski, N.
Zwick, C.
Held, G.
Pfreundschuh, M.
HAEMATOLOGICA, 2013, 98 : 131 - 131
[10] Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)
Pfreundschuh, Michael
Zeynalova, Samira
Poeschel, Viola
Haenel, Mathias
Schmitz, Norbert
Hensel, Manfred
Reiser, Marcel
Loeffler, Markus
Schubert, Joerg
BLOOD, 2007, 110 (11) : 243A - 243A

← 1 2 3 4 5 →